Buy Furadantin Online

Furadantin (nitrofurantoin)

THERAPEUTIC CLASS

Imidazolidinedione antibacterial

DEA CLASS

RX

INDICATIONS

Treatment of UTIs caused by susceptible strains of microorganisms.

ADULT DOSAGE

Urinary Tract Infections

Usual:
50-100mg qid; use the lower dosage levels for uncomplicated infections
Continue for 1 week or at least 3 days after sterility of the urine is obtained

Long-Term Suppressive Therapy:

Reduce to 50-100mg hs may be adequate

PEDIATRIC DOSAGE

Urinary Tract Infections

≥1 Month of Age:
Usual:
5-7mg/kg/24 hrs given in 4 divided doses
Average Weight-Based Dosing:
7-11kg: 2.5mL qid
12-21kg: 5mL qid
22-30kg: 7.5mL qid
31-41kg: 10mL qid
≥42kg: See Adult Dosage

Continue for 1 week or at least 3 days after sterility of the urine is obtained

Long-Term Suppressive Therapy:
Doses as low as 1mg/kg/24 hrs, given in a single dose or in 2 divided doses, may be adequate

ADMINISTRATION

Oral route

Shake vigorously
Take w/ food

HOW SUPPLIED

Sus: 25mg/5mL [230mL]

CONTRAINDICATIONS

Anuria, oliguria, significant renal impairment (CrCl <60mL/min or clinically significant elevated SrCr), pregnancy at term (38-42 weeks gestation), during labor and delivery, or when the onset of labor is imminent, neonates <1 month of age, previous history of cholestatic jaundice/hepatic dysfunction associated with nitrofurantoin.

WARNINGS/PRECAUTIONS

Not for treatment of pyelonephritis or perinephric abscesses. Many patients who undergo treatment are predisposed to persistence/reappearance of bacteriuria; if this occurs after treatment, select other therapeutic agents with broader tissue distribution. Acute, subacute, or chronic pulmonary reactions reported; d/c and take appropriate measures if these occur. Hepatic reactions (eg, hepatitis, cholestatic jaundice, chronic active hepatitis, hepatic necrosis) occur rarely; withdraw immediately and take appropriate measures if hepatitis occurs. Peripheral neuropathy, which may become severe or irreversible, reported; may enhance the chance of occurrence with renal impairment, anemia, diabetes mellitus (DM), electrolyte imbalance, vitamin B deficiency, and debilitating disease. Optic neuritis reported rarely. Therapy induced hemolytic anemia of the primaquine-sensitivity type reported; d/c therapy if hemolysis occurs. Clostridium difficile-associated diarrhea (CDAD) reported; d/c therapy is CDAD is suspected/confirmed. A false (+) reaction for glucose in urine may occur with Benedict's and Fehling's sol.

ADVERSE REACTIONS

Pulmonary hypersensitivity reactions, peripheral neuropathy, nausea, anorexia, emesis, dizziness, asthenia, vertigo, nystagmus, headache, drowsiness, alopecia, angioedema, pruritus, myalgia.

DRUG INTERACTIONS

Antacids-containing magnesium trisilicate reduce both the rate and extent of absorption. Uricosuric drugs (eg, probenecid, sulfinpyrazone) may inhibit renal tubular secretion resulting in increased levels that may increase toxicity, and decreased urinary levels that could lessen its efficacy.

PREGNANCY AND LACTATION

Category B, not for use in nursing.

MECHANISM OF ACTION

Imidazolidinedione antibacterial; reduced by a wide range of enzymes including bacterial flavoproteins to reactivate intermediates, which are damaging to macromolecules such as DNA and proteins.

PHARMACOKINETICS

Absorption: Readily absorbed. Distribution: Found in breast milk. Elimination: (100mg qid for 7 days) Urine (42.7% [Day 1], 43.6% [Day 7]).

ASSESSMENT

Assess for drug hypersensitivity, anuria, oliguria, significant renal impairment, history of cholestatic jaundice/hepatic dysfunction associated with therapy, G6PD deficiency, DM, anemia, electrolyte imbalance, vitamin B deficiency, debilitating disease, pregnancy/nursing status, and possible drug interactions. Obtain urine specimens for culture and susceptibility testing prior to therapy.

MONITORING

Monitor for persistence or reappearance of bacteriuria, pulmonary reactions, peripheral neuropathy, optic neuritis, hematologic abnormalities, CDAD, and other adverse reactions. Obtain urine specimens for culture and susceptibility testing after completion of therapy. Monitor renal and pulmonary function periodically during long-term therapy. Monitor LFTs periodically. Monitor periodically for changes in biochemical tests that would indicate liver injury.

PATIENT COUNSELING

Inform of the potential risks and benefits of therapy. Advise to take with food to further enhance tolerance and improve drug absorption. Instruct to complete full course of therapy and advise to contact physician if any unusual symptoms occur during therapy. Inform that diarrhea is a common problem that usually ends when antibiotic is discontinued. Inform that watery and bloody stools (with/without stomach cramps and fever) may develop even as late as 2 or more months after having taken the last dose; instruct to contact physician as soon as possible if this occurs. Advise not to use antacid preparations containing magnesium trisilicate while taking therapy.

STORAGE

20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F). Avoid exposure to strong light. Protect from freezing. Shake vigorously. Use within 30 days.

TAGS

furadantin oral suspension price, neo furadantin 50 prezzo, furadantin suspension, furadantin suspension dosage, neo furadantin prezzo, buy furadantin, furadantin oral suspension package insert, furadantin prezzo farmacia, furadantin suspension price, furadantin nitrofurantoin oral suspension, furadantin prezzo, furadantin suspension storage, furadantin 100 prezzo, furadantin buy online, neo furadantin 50 mg prezzo, furadantin suspension package insert, furadantin oral suspension dosage, prezzo del furadantin, furadantin cistite prezzo, neo furadantin 100 prezzo, furadantin oral suspension